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REDUCTION OF ACUTE OTITIS MEDIA IN CHILDREN: A COST-CONSEQUENCE ANALYSIS OF THE NEW 10-VALENT PNEUMOCOCCAL NON-TYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN-D CONJUGATE VACCINE (PHID-CV) COMPARED WITH THE 7-VALENT PNEUMOCOCCAL VACCINE (PCV-7)
Pereira JA J , Ismaila AS, Robson RC, Simpson SD GlaxoSmithKline, Mississauga, ON, Canada OBJECTIVES: Acute otitis media (AOM) is a prevalent pediatric condition, affecting approximately 80% of children by three years of age. Routine immunization programs include 7-valent Pneumococcal conjugate vaccine (PCV-7), associated with a reduction of AOM events caused by Streptococcus pneumoniae. The objective of this study was to compare the costs and effects of PCV-7 with PHiD-CV, a newly approved in Canada Pneumococcal non-typeable Haemophilus infl uenzae Protein D-conjugate vaccine employing an active protein D-carrier associated with reduction of nontypeable Haemophilus Infl uenzae (NTHi) AOM. METHODS: A steady-state, population-based model with a one-year time horizon was developed, and calibrated with Canadian epidemiologic and demographic data, to investigate the costs and effects associated with AOM episodes across the Canadian population. A 4-dose schedule for PHiD-CV vaccination was compared with a 4-dose schedule for PCV-7 vaccination. The basecase included herd-protection for invasive pneumococcal disease and serotype 6A cross protection. A health care system perspective was taken with the assumption of 100% vaccination coverage. RESULTS: Compared with PCV-7, vaccination with PHiD-CV could prevent an additional 170,951 ambulatory visits for AOM, 144,454 antibiotic prescriptions for AOM, and 9,830 hospitalizations for myringotomy per year. With PCV-7 the total direct costs associated with AOM are $119.8 million of which $16.9 million could be off-set by implementation of routine vaccination with PHiD-CV. CONCLUSIONS: Based on the base-case analysis, inclusion of PHiD-CV in routine immunization programs across Canada would be cost-saving to the health care system compared with PCV-7. PHiD-CV offers substantial benefi ts in terms of reduced ambulatory visits, antibiotic prescriptions and hospitalizations for AOM, a highly prevalent childhood condition. Psoriasis is a chronic debilitating immune-mediated infl ammatory disease, with no cure, affecting an estimated one million Canadians. Studies show that up to 85% of psoriasis is of plaque type and up to 25% of sufferers have either moderate or severe disease. There are no reliable estimates of the economic burden of psoriasis in Canada. The objective is to estimate the economic burden of moderate to severe chronic plaque psoriasis in Canada in 2008, inclusive of direct medical and non-medical, and lost productivity costs. METHODS: Using a cross-sectional design, data were collected on 90 patients diagnosed with moderate or severe chronic plaque psoriasis in three dermatology clinics (British Columbia, Ontario, and Quebec). Data were obtained from three sources: clinic charts determining medical resources utilized for treatment; patient questionnaires eliciting information on non-medical resources utilized, lost productivity, and the impact on quality of life (QoL) using the Dermatology Quality of Life Index (DLQI); and unit costs (all in CDN$2008) from published sources. RESULTS: The estimated mean annual costs of treating patients with moderate to severe chronic plaque psoriasis was $7966/patient, of which $4524 (95% confi dence interval (CI): $2246 to $6802) was due to direct medical and non-medical costs, and $3442 (95% CI: $1293 to $5590) was due to lost productivity. The estimated mean DLQI of 6.7 is refl ective of a moderate impact on QoL in moderate to severe psoriasis patients. CONCLUSIONS: Extrapolating these costs to the estimated number of affected Canadians means that moderate to severe psoriasis costs on the order of $961.3 million (95% CI: $477.3 million to $1.4 billion) in direct medical and non-medical costs annually. The total cost to society is approximately $1.7 billion (95% CI: $752.0 million to $2.6 billion). This economic burden coupled with the QoL effect indicates the need for more effi cient and long-term control.
PSS10 ECONOMIC BURDEN OF MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS IN CANADA
PSS11 ECONOMIC BURDEN OF SEVERE CHRONIC HAND ECZEMA/ DERMATITIS IN CANADIAN ADULTS
Piwko C 1 , Vicente C 1 , Bereza BK 1,2 , Ventin A 3 1 PIVINA Consulting Inc, Thornhill, ON, Canada, 2 University of Toronto, Toronto, ON, Canada, 3 Basilea Pharmaceuticals Corp., Toronto, ON, Canada OBJECTIVES: Severe Chronic Hand Eczema (CHE) or Chronic Hand Dermatitis (CHD), is characterized by thick scaly skin causing painful fi ssures, erythema, itching, blustering and oedema. Severe CHE/CHD is often unresponsive to conventional topical corticosteroids and results in substantial occupational, personal, and psychological disability. There is currently a lack of information regarding the economic burden of CHE/CHD in Canada. METHODS: A dynamic Excel model was developed to estimate the cost of treating adults with severe CHE in Canada. Epidemiological/clinical data were derived from systematic literature searches. A Delphi panel of dermatologists provided estimates of resource utilization and validated epidemiological/clinical rates. Given the impact on lost productivity, a pseudo societal perspective was chosen; out of pocket expenses (travel and non-prescription pharmacotherapies) were excluded from the analysis. Unit costs were derived from Ontario standard lists and reported as 2008 Canadian dollars. RESULTS: In 2008 the estimated adult population was 26 million. From the literature it was determined that 10% of adults may be affected by CHE, of those 6.7% may have severe CHE/CHD. Asscessing 50% of these patients don't adequately respond to topical corticosteroids, an estimated 87,200 Canadians have severe CHE being refractory to topicals. Treatment costs, including lost productivity, was calculated to be $737 million per annum. Even assuming current second-line treatment options are 100% effective, the cost of severe CHE was estimated to be $390 million per annum. CONCLUSIONS: This study estimated the costs of severe CHE/CHD unresponsive to topical corticosteroids in Canada ranges from $390-$737 million per annum. The majority of costs comes from lost productivity due to disease and accessing treatment.
